No Added Benefit From Renal-Artery Stenting, Long-Delayed Study Concludes
This article was originally published in The Gray Sheet
Executive Summary
The 947-patient CORAL trial shows renal-artery stenting does not prevent more adverse events than comprehensive medical therapy alone in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease.
You may also be interested in...
Medicare Coverage Advisers Split On Renal Artery Stenting
CMS' Medicare Evidence Development Coverage Advisory Committee (MedCAC) could not reach consensus on whether Medicare coverage of angioplasty and stenting to treat renal artery disease should be limited to patients in clinical trials
Does Coverage Of Renal Intervention Hinder Trials? Stakeholders Disagree
Stakeholders are split on whether Medicare should continue covering percutaneous renal artery intervention or limit it in order to encourage enrollment in randomized trials
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”